What will become of the German antidiabetics market?
This article was originally published in Scrip
Executive Summary
Yet another company – this time Novo Nordisk – has decided that it wouldn't be good business to sell its antidiabetic in Germany following a rocky ride through the AMNOG benefit assessment and pricing negotiations. While companies are worried about the future of treatments for chronic diseases in Germany, prescribers and health insurers are more sanguine and believe that German patients are not yet missing out on important innovations in the market.